Renovaro Inc. (NASDAQ:RENB) Major Shareholder Sells $30,955.14 in Stock

Renovaro Inc. (NASDAQ:RENB) major shareholder Anderson Wittekind William sold 21,954 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $1.41, for a total value of $30,955.14. Following the completion of the transaction, the insider now directly owns 875,795 shares in the company, valued at $1,234,870.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Anderson Wittekind William also recently made the following trade(s):

• On Thursday, July 11th, Anderson Wittekind William sold 14,896 shares of Renovaro stock. The shares were sold at an average price of $1.51, for a total value of $22,492.96.
• On Tuesday, July 9th, Anderson Wittekind William sold 4,630 shares of Renovaro stock. The shares were sold at an average price of $1.53, for a total value of $7,083.90.
• On Friday, July 5th, Anderson Wittekind William sold 60,000 shares of Renovaro stock. The shares were sold at an average price of $1.55, for a total value of $93,000.00.
• On Wednesday, July 3rd, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The shares were sold at an average price of $1.51, for a total value of $75,500.00.
• On Monday, July 1st, Anderson Wittekind William sold 60,000 shares of Renovaro stock. The shares were sold at an average price of $1.56, for a total value of $93,600.00.
• On Thursday, June 27th, Anderson Wittekind William sold 14,671 shares of Renovaro stock. The stock was sold at an average price of $1.50, for a total value of $22,006.50.
• On Tuesday, June 25th, Anderson Wittekind William sold 20,000 shares of Renovaro stock. The stock was sold at an average price of $1.58, for a total value of $31,600.00.
• On Friday, June 14th, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The stock was sold at an average price of $1.58, for a total value of $79,000.00.

Renovaro Stock Performance

Renovaro stock traded up $0.02 during midday trading on Wednesday, hitting $1.44. 301,068 shares of the company were exchanged, compared to its average volume of 522,451. The firm has a market capitalization of $212.41 million, a PE ratio of -1.86 and a beta of 0.60. Renovaro Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $5.25. The business has a fifty day simple moving average of $1.40 and a two-hundred day simple moving average of $2.44.

Renovaro (NASDAQ:RENB) last posted its earnings results on Wednesday, May 15th. The company reported ($0.08) EPS for the quarter.

Institutional Trading of Renovaro

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new position in Renovaro during the first quarter worth approximately $46,000. Tidal Investments LLC purchased a new position in Renovaro during the first quarter worth approximately $98,000. Finally, Vanguard Group Inc. boosted its position in Renovaro by 904.0% during the first quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock worth $10,379,000 after purchasing an additional 3,526,565 shares in the last quarter. 71.41% of the stock is owned by institutional investors and hedge funds.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.